Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-23T04:30:43.796Z Has data issue: false hasContentIssue false

Amisulpride in dysthymia: results of a naturalistic study in general practice

Published online by Cambridge University Press:  16 April 2020

M Paes de Sousa*
Affiliation:
Department of Psychiatry, Hospital de Santa Maria, Av Egas Moniz 1600 Lisbon, Portuga
Get access

Summary

A naturalistic study was conducted in general practice in Portugal on the efficacy and tolerance of low doses of amisulpride in the treatment of dysthymia. A total of 109 patients received low doses (50 – 100 mg) of amisulpride for four weeks. A global evaluation showed good or very good efficacy and tolerance in more than 80% of the patients. The social disability observed at baseline was significantly improved after the four-week treatment period. Few adverse events were observed and only four patients dropped out due to side effects. Our results suggest that low doses of amisulpride might be a safe and effective treatment for dysthymia in clinical practice.

Type
Research Article
Copyright
Copyright © Elsevier paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boyer, PLecrubier, YPuech, A et al. Treatment of dysthymia with low doses of amisulpride vs aminepline. Clin Neuropharmacol 1992; 15(1B):23CrossRefGoogle Scholar
Deniker, PGinestet, DNeuroleptiques. In: Encycl Méd-Chir Psychiatrie. 37860 B20. Paris: Elsevier, 1973Google Scholar
Gekière, FRoger, BSoret, CBorenstein, PBiological tolerance of amisulpride with long-term treatment. In:Borenstein, et al. Amisulpride. Paris: Expansion Scientifique Française, 1989; 181–7Google Scholar
Gessa, GDysthymia and depressive disorders: dopamine hypothesis. Eur Psychiatry 1996:this issueGoogle Scholar
Jenner, PMarsden, CDSubstituted benzamide drugs as selective neuroleptic agents. Neuropharmacology 1981; 20:1285–93Google ScholarPubMed
Lecrubier, YPuech, ASimon, PWidlocher, DSchizophrénie: hyper ou hypofonctionnement du système dopaminergique? Une hypothèse bipolaire. Psychologie Méd 1980; 12:2431–41Google Scholar
Lecrubier, YPuech, AJAubin, FBoyer, PDeyrieux, BImprovement by amisulpride of the negative syndrome in non-psychotic subjects. A preliminary study. Psychiatry Psychobwl 1988; 3(5):329–33CrossRefGoogle Scholar
Lecrubier, YPuech, AJBoyer, PThe Contribution of Neuropharmacology to the Understanding of Ill-Defined Psychological Disorders. In: Sartorius, NGoldberg, Dde Girolamo, GCosta e Silva, JALecrubier, YWittchen, Psychological Disorders in General Medical Settings. New York: Hogrefe & Huber Publishers, 1990; 98110Google Scholar
Protais, PHermier, CCostentin, JThe discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 1985; 24:861867CrossRefGoogle ScholarPubMed
Puech, ASimon, PBoissier, JRBenzamides and classical neuroleptics. Comparison of their action using 6-apomorphine- induced effects. Eur J Pharmacol 1978; 50:291300CrossRefGoogle Scholar
Sedvall, CAlfredsson, GBjerkenstedt, LHarnryd, COxenstierna, GWiesel, FAClinical, biochemical and pharmacokinetic studies of sulpiride in schizophrenic patients. In: Ackenheil, MMatussek, MSpecial aspects of psychopharmacology. Paris: Expansion Scientifique Française, 1983; 153–70Google Scholar
Sheehan, DVThe anxiety disease. New York: Scribner and Sons, 1983Google Scholar
Sokoloff, PMartres, MPSchwartz, JCThree classes of dopamine receptor (D2, D3, D4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Naunyn-Schmiedeberg's Arch Pharmacol 1980; 315:89102CrossRefGoogle Scholar
WPA Dysthymia Working Group Dysthymia in clinical practice. Br J Psychiatry 1995; 166:174–83CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.